dexefaroxan

Dexefaroxan is an investigational small molecule drug that has historically been studied as an alpha-2 adrenergic receptor antagonist with potential cognitive-enhancing and neuroprotective properties. It is not approved for medical use and does not have a well-defined clinical development program or approved indications. Dexefaroxan is structurally related to idazoxan and has been evaluated in preclinical and early clinical studies primarily for its effects on cognition and neurotransmitter regulation. Its mechanism of action involves selective antagonism of alpha-2 adrenergic receptors, which results in increased levels of norepinephrine and modulation of other neurotransmitter systems in the central nervous system. There is minimal recent information regarding its development, approval status, or commercial availability.

Other names

R-Idazoxan Hydrochloride Extended-Release